Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir

International Journal of Cancer

Volumn 123, Issue 2, 2008, Pages 476-483

  Hernlund, Emma ^a   Ihrlund, Linda Strandberg ^a   Khan, Omar ^a,b   Ates, Yildiz Ozlem ^a,c   Linder, Stig ^a   Panaretakis, Theocharis ^a,d   Shoshan, Maria C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c SABANCI UNIVERSITY   (Turkey)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

oxidation; Antiproliferation; Apoptosis; Chemopotentiation; Glycolysis

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETULIC ACID; CAMPTOTHECIN; CISPLATIN; CURCUMIN; DEOXYGLUCOSE; ECHINOMYCIN; ELLIPTICINE; ETOMOXIR; ETOPOSIDE; FLUOROURACIL; LITHIUM CHLORIDE; LONIDAMINE; METHOTREXATE; OXALIPLATIN; PIROXICAM; QUERCETIN; TRIETHYLPHOSPHINE GOLD; UO 126; ADENOSINE TRIPHOSPHATE; EPOXIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; ENERGY YIELD; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; CARCINOMA; CELL PROLIFERATION; CELL STRAIN HCT116; COLON TUMOR; DRUG EFFECT; ENERGY METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION; TIME;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; CISPLATIN; COLONIC NEOPLASMS; DEOXYGLUCOSE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENERGY METABOLISM; EPOXY COMPOUNDS; HCT116 CELLS; HUMANS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 44949149074     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23525     Document Type: Article

References (39)

1. Persons DA, Schek N, Hall BL, Finn OJ. Increased expression of glycolysis-associated genes in oncogene-tansformed and growth-accelerated states. MoI Carcinog 1989;2:88-94.
2. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29:339-43.
3. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;157:170-8.
4. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002;62:6674-81.
5. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006;18:598-608.
6. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, Vendemelio M, George A, Bartholomew R, Carlo D, Shaikh A, Kupperman J, Newell EW, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 2002;16:1550-7.
7. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, Cejas P, Hardisson D, Fresno Vara JA, Belda-Iniesta C, Gonzalez-Baron M, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005;26:2095-104.
8. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005;102:5992-7.
9. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, Banerjee AK, Das S, Jena A, Ravichandran R, Sahi UP, Kumar R, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol BiolPhys 1996;35:103-11.
10. Khaitan D, Chandna S, Arya MB, Dwarakanath BS. Differential mechanisms of radiosensitization by 2-deoxyglucose in the monolayers and multicellular spheroids of a human glioma cell line. Cancer Biol Ther 2006;5:1142-51.
11. Varshney R, Dwarakanath B, Jain V. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells. Int J Radiat Biol 2005;81:397-408.
12. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-4.
13. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, new targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65.
14. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechn 2006;7:483-93.
15. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate used as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 2006;3:490-8.
16. Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, Shoshan M, Linder S. A novel high-through-put assay for screening of proapoptotic drugs. Investig New Drugs 2002;20:253-9.
17. van der Kuip H, Murdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006;6:86.
18. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
19. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death. Exp Cell Res 2003;283:1-16.
20. Kim JB, Stein R, O'Hare MJ. Three dimensional in vitro tissue culture models of breast cancer - a review. Breast Cancer Res Treat 2004;85:281-91.
21. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-85.
22. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2006;120:175-80.
23. Landau BR, Lubs HA. Animal responses to 2-deoxy-D-glucose administration. Proc Soc Exp Biol Med 1958;99:124-7.
24. Hinderling VB, Schrauwen P, Langhans W, Westerterp-Plantega MS. The effect of etomoxir on 24-h oxidation and satiety in humans. Am J Clin Nutr 2002;76:141-7.
25. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;18:1272-82.
26. Goodisman J, Hagrman D, Tacka KA, Souid AK. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006;57:257-67.
27. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces ER stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278:9100-106.
28. Hägg M, Mandic A, Zhou R, Shoshan MC, Linder S. ER stress induced by ellipticine plant alkaloids. Mol Cancer Ther 2004;3:489-97.
29. Yung HW, Wyttenbach A, Tolkovsky AM. Aggravation of necrotic death of glucose-deprived cells by MEK1 inibitors UO126 and PD184161 through depletion of ATP. Biochem Pharmacol 2004;68:351-60.
30. Fonseca CP, Jones JG, Carvalho RA, Jeffrey FM, Montezinho LP, Geraldes CF, Castro MM. Tricarboxylic acid cycle inhibition by Li+ in the human neuroblastoma SH-SY5Y cell line: a 13C NMR isotopomer analysis. Neurochem Int 2005;47:385-93.
31. Wei Y, Wang D, Topczewski F, Pagliasotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006;291:E275-E281.
32. Zhou R, Vander Heiden MG, Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res 2002;62:3515-20.
33. Psahoulia FH, Moumtzi S, Roberts ML, Sasazuki T, Shirasawa S, Pintzas A. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis 2007;28:1021-31.
34. Robaszkiewicz A, Balcerczyk A, Bartosz G. Antioxidative and prooxidative effect of quercetin on A549 cells. Cell Biol Int 2007;31:1245-60.
35. Lee LT, Huang YT, Hwang JJ, Lee AY, Ke FC, Huang CJ, Kandaswami C, Lee PP, Lee MT. Transinactivation of the EGFR tyrosine kinase and FAK phosphorylation by dietary flavonoids. Biochem Pharmacol 2004;67:2103-14.
36. Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004;25:647-59.
37. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005;24:980-91.
38. Dbaibo GS, Kfoury Y, Darwiche N, Panjarian S, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de Thé H, Bazarbachi A. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult. T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity. Haematologica 2007;92:753-62.
39. Kitareewan S, Roebuck BD, Demidenko E, Sloboda RD, Dmitrovsky E. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 2007;99:41-52.